Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. In the past five years, ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

3. Justifying its valuation with its outlook Eli Lilly's valuation might be a significant stumbling block for some investors. If the stock fails to meet the market's lofty expectations, its shares ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have set the standard thus far. MariTide isn't approved, but even if it is, if ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.